Gene: MYO3B

140469
-
myosin IIIB
protein-coding
2q31.1
Ensembl:ENSG00000071909 MIM:610040 Vega:OTTHUMG00000154002 UniprotKB:Q8WXR4
NG_034020.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.690e-1 (AD)  9.803e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GPRIN20.568
SYTL50.567
TENM10.546
SCN7A0.543
COL25A10.535
GLRA20.524
BCAT10.511
PLD50.505
AMOTL10.501
PKIB0.5

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SLC7A9-0.314
CLDN9-0.31
PTH1R-0.301
NPIPB6-0.3
RFX2-0.294
KLK14-0.285
ZNF296-0.284
FAM186A-0.284
MMP23B-0.283
OLAH-0.283

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO3B mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO3B mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO3B mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO3B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO3B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO3B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO3B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO3B mRNA"27188386
C496492abrineabrine results in decreased expression of MYO3B mRNA22595364
D020106AcrylamideAcrylamide results in decreased expression of MYO3B mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of MYO3B gene27153756
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of MYO3B mRNA24449571
D001104ArbutinArbutin results in decreased expression of MYO3B mRNA17103032
D001151ArsenicArsenic affects the methylation of MYO3B gene25304211
D001280AtrazineAtrazine results in decreased expression of MYO3B mRNA23358194
C487081belinostatbelinostat results in increased expression of MYO3B mRNA26272509
C006780bisphenol Abisphenol A results in decreased expression of MYO3B mRNA24586524
C006780bisphenol Abisphenol A results in decreased expression of MYO3B mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of MYO3B gene28505145
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in decreased expression of MYO3B mRNA23649840
C069837fullerene C60fullerene C60 results in decreased expression of MYO3B mRNA19167457
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of MYO3B mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of MYO3B mRNA23649840
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of MYO3B mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of MYO3B mRNA"25554681
C028007nickel monoxidenickel monoxide results in decreased expression of MYO3B mRNA19167457
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO3B mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of MYO3B mRNA26272509
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MYO3B mRNA21570461
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO3B mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of MYO3B mRNA24935251|2627250
C015559trimellitic anhydridetrimellitic anhydride results in decreased expression of MYO3B mRNA19042947
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYO3B mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of MYO3B mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of MYO3B mRNA23179753|2627250
D014635Valproic AcidValproic Acid results in increased expression of MYO3B mRNA24383497|2800136
C034028vanadyl sulfatevanadyl sulfate results in decreased expression of MYO3B mRNA16330358
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of MYO3B gene25560391
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYO3B mRNA"27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003777microtubule motor activity-IEA-  
GO:0003779actin binding-IEA-  
GO:0004674protein serine/threonine kinase activity-IEA-  
GO:0005524ATP binding-IEA-  
GO:0008017microtubule binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006468protein phosphorylation-IEA-  
GO:0007018microtubule-based movement-IEA-  
GO:0007601visual perception-IEA-  
GO:0007605sensory perception of sound-ISS-  
GO:0050896response to stimulus-IEA-  
GO:0090103cochlea morphogenesis-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005737cytoplasm-IEA-  
GO:0016459myosin complex-IEA-  
GO:0032426stereocilium tip-ISS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23376709A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer. (2013 Jul)Kerns SLJ Urol